Shamblaw, Amanda L.
11  results:
Search for persons X
?
6

Week 96 efficacy and safety results of the phase 3, randomi..:

Eron, Joseph ; Orkin, Chloe ; Cunningham, Douglas...
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.antiviral.2019.104543.  , 2019
 
?
7

Week 96 efficacy and safety results of the phase 3, randomi..:

Eron, Joseph ; Orkin, Chloe ; Cunningham, Douglas...
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.antiviral.2019.104543.  , 2019
 
?
8

Week 96 efficacy and safety results of the phase 3, randomi..:

Eron, Joseph ; Orkin, Chloe ; Cunningham, Douglas...
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.antiviral.2019.104543.  , 2019
 
?
9

Week 96 efficacy and safety results of the phase 3, randomi..:

Eron, Joseph ; Orkin, Chloe ; Cunningham, Douglas...
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.antiviral.2019.104543.  , 2019
 
?
10

Week 96 efficacy and safety results of the phase 3, randomi..:

Eron, Joseph ; Orkin, Chloe ; Cunningham, Douglas...
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.antiviral.2019.104543.  , 2019
 
?
11

Week 96 efficacy and safety results of the phase 3, randomi..:

Eron, Joseph ; Orkin, Chloe ; Cunningham, Douglas...
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.antiviral.2019.104543.  , 2019
 
1-11